Skip to content
DataLookout
Menu

PIKASSO-01NCT05307705

A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors

StatusActive, Not Recruiting
PhasePhase 1
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 48 versions: 38 with changes below, 10 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Primary endpoints: details revised at 2 of 2 entries Show 4 more changesShow less
    • Enrollment closed, study ongoing
    • Primary completion date changed from estimate of Dec 2026 to Apr 2, 2025
    • Eligibility criteria expanded, about 45 words
    • Site details revised at 50 of 50 sites
  2. Minor Site details revised at 4 of 50 sitesv47
  3. Minor Site details revised at 6 of 50 sitesv46
  4. Notable Trial status changed: Active, Not Recruiting → Recruiting
    • Enrollment increased: 193 → 260 participants
    • Site details revised at 50 of 50 sites
    v45
  5. Minor Trial sites expanded: 45 → 50 locationsv44
Show 32 earlier versionsHide 32 earlier versions
  1. Minor Study sites: 50 to 45v43
  2. Notable Primary and study completion dates: Dec 2025 to Dec 2026v41
  3. Minor Site details revised at 20 of 50 sitesv37
  4. Notable Primary completion date: May 2025 to Dec 2025
    • Study sites: 55 to 50
    v35
  5. Minor Study completion date: May 2025 to Dec 2025
    • Study sites revised (55)
    v34
  6. Minor Collaborators shortened, about 3 wordsv32
  7. Minor Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 400 to confirmed 193
    • Site details revised at 55 of 55 sites
    v30
  8. Minor Site details revised at 1 of 55 sitesv28
  9. Minor Study sites: 48 to 55v27
  10. Minor Study sites: 44 to 48v26
  11. Minor Study sites: 41 to 44v25
  12. Minor Study sites: 39 to 41v24
  13. Minor Study sites: 35 to 39v23
  14. Minor Study sites: 33 to 35v22
  15. Minor Study sites: 31 to 33v21
  16. Notable Primary endpoints revised (2)
    • Eligibility criteria expanded, about 18 words
    • Secondary endpoints: details revised at 1 of 10 entries
    v20
  17. Minor Study sites: 24 to 31v19
  18. Minor Study sites: 23 to 24v18
  19. Minor Study sites: 21 to 23v17
  20. Minor Study sites: 20 to 21v16
  21. Minor Study sites: 14 to 20v15
  22. Minor Enrollment target: 300 to 400
    • Eligibility criteria expanded, about 34 words
    • Study arms: 6 to 7
    v14
  23. Minor Study sites: 12 to 14v13
  24. Minor Study sites: 11 to 12v12
  25. Minor Study sites: 10 to 11v10
  26. Minor Study sites: 8 to 10v9
  27. Minor Study sites: 7 to 8v8
  28. Minor Enrollment target: 260 to 300
    • Study sites: 5 to 7
    • Eligibility criteria expanded, about 9 words
    v7
  29. Minor Study sites: 4 to 5v5
  30. Minor Site contacts updated at 4 of 4 sitesv4
  31. Notable Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 4
    • Start date changed from estimate of Apr 2022 to May 11, 2022
    v3
  32. Study Status, Referencesv2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Phase 1 a: To determine the maximum tolerated dose/recommended phase 2 dose (MTD/RP2D) of LOXO-783: Number of patients with dose-limiting toxicities (DLTs)
Timeframe: During the first 28-day cycle of LOXO-783 treatment
Phase 1 a: To determine the MTD/RP2D of LOXO-783: Number of patients with DLT-equivalent toxicities
Timeframe: During the first 28-day cycle of LOXO-783 treatment

Secondary (10)

To assess the pharmacokinetics (PK) of LOXO-783: Area under the concentration versus time curve (AUC)
To assess the PK of LOXO-783: Maximum drug concentration (Cmax)
To evaluate the preliminary antitumor activity of LOXO-783: Overall response rate (ORR)
To evaluate the preliminary antitumor activity of LOXO-783: Best overall response (BOR)
To evaluate the preliminary antitumor activity of LOXO-783: Duration of response (DOR)
Show 5 moreShow less
To evaluate the preliminary antitumor activity of LOXO-783: Disease control rate (DCR)
To evaluate the preliminary antitumor activity of LOXO-783: Clinical benefit rate (CBR)
To evaluate the preliminary antitumor activity of LOXO-783: Time to response (TTR)
To evaluate the preliminary antitumor activity of LOXO-783: Progression free survival (PFS)
To evaluate the preliminary antitumor activity of LOXO-783: Overall survival (OS)

Arms and interventions

Phase 1A: LOXO-783 Monotherapy Dose EscalationExperimental

LOXO-783 administered orally

Phase 1B: Part AExperimental

LOXO-783 administered orally in combination with fulvestrant intramuscularly, imlunestrant orally, or an aromatase inhibitor orally

Phase 1B: Part BExperimental

LOXO-783 orally in combination with abemaciclib and either physician's choice aromatase inhibitor orally, fulvestrant intramuscularly, or imlunestrant orally

Phase 1B: Part CExperimental

LOXO-783 orally in combination with fulvestrant intramuscularly

Phase 1B: Part DExperimental

LOXO-783 orally in combination with paclitaxel intravenously

Phase 1B: Part EExperimental

LOXO-783 orally

Phase 1B: Part FExperimental

Multiple randomized dose levels of LOXO-783 orally with fulvestrant intramuscularly

Drugs: LOXO-783, Fulvestrant, Imlunestrant, Abemaciclib, Anastrozole, Exemestane, or Letrozole, Paclitaxel

Sites

50 sites in 12 countries

United States 17, Spain 8, France 5, Japan 4, Australia 3, China 3, Belgium 2, Canada 2, South Korea 2, United Kingdom 2, Germany 1, Singapore 1